



SHAREABLE PDF

The value of serology testing to manage SARS-CoV-2 infections

Laia Fernández-Barat^{1,2,3}, Ruben López-Aladid^{1,2,3} and Antoni Torres ^{1,2,3}

Affiliations: ¹Cellex Laboratory, CibeRes (Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, 06/06/0028), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain. ²School of Medicine, University of Barcelona, Barcelona, Spain. ³Dept of Pneumology, Thorax Institute, Hospital Clinic of Barcelona, Barcelona, Spain.

Correspondence: Antoni Torres, Dept of Pneumology, Thorax Institute, Hospital Clinic of Barcelona, Villarroel 170, Barcelona, Catalunya 08036, Spain. E-mail: atorres@clinic.cat

 @ERSpublications

Validated serology tests are a good complement for the SARS-CoV-2 RNA test, allow rapid epidemiological control and reveal immune status before and after vaccination. <https://bit.ly/3eKAc6h>

Cite this article as: Fernández-Barat L, López-Aladid R, Torres A. The value of serology testing to manage SARS-CoV-2 infections. *Eur Respir J* 2020; 56: 2002411 [<https://doi.org/10.1183/13993003.02411-2020>].

This single-page version can be shared freely online.

The figures presented in the World Health Organization's latest report on the current status of the coronavirus disease 2019 (COVID-19) pandemic and the COVID-19 dashboard of the Johns Hopkins University of Medicine are quite similar: respectively, 6,416,828 and 6,656,827 cases worldwide, and 382 867 and 391 571 deaths [1, 2].